Loading viewer...
investor_presentation
Format: PDF investor_presentation
2017 Full Year Results 27 March 2018 (HKEx : 02018)
2017 Full Year Results
(HKEx : 02018)1YoY Performance
Unit: RMB mn FY2017 FY2016 YoY
Revenue 21,119 15,507 +36%
Gross Profit 8,720 6,443 +35%
Gross Profit Margin 41.3% 41.5% -0.2ppt
Net Profit 5,325 4,026 +32%
Net Profit Margin 25.2% 26.0% -0.8ppt
(Weighted average, million)1,225 1,228
Basic EPS (RMB) 4.35 3.28 +33%
Dividend (HK$) 2.10 1.47 +43%2
67% 52%51%45%20%38%45%50%
2014 2015 2016 2017RMB Million PAST 3 YEARS REVENUE GROWTH AND % BREAKDOWN BY SEGMENTS
Haptic and RF/Mechanical
Others Total Revenue+32%+32%+36%3Segments review: FY 2017 vs FY 2016
Acoustic sales up 20%; successfully launched new design platform –SLS, and higher
specs of stereo sound, waterproof continued higher penetration
Haptic and RF segment grew 51%; For Haptics, developed a range of different specs
solutions for market demand for upgrading touch sense UX; In RF, penetrated into
mainstream Android flagships as planned. Both sub -segments expected wider
penetration into Android market.
Optics: WLG is ready and gained wide positive market interests; plastic lenses more
than 10 millions sets monthly shipments end of 2017 and obtained wide market
Mems Components: sales up 58% with shipments growth; acquired some IPs
portfolio on Mems design for strengthening market position4
FY2016 FY2017RMB Million ACOUSTIC SALES
+42%7,9569,5805Future Growth Drivers
Optics: unique hybrid lens solutions to capture market opportunities of 3D
sensing and high specs imaging designs
Acoustic: innovative new structure designs(SLS) for evevating audio
Preview truncated — download the full document for the complete content.
investor_presentation
10 Pages
investor_presentation
33 Pages
Tonix Pharmaceuticals Holding Corp.
Cullinan Therapeutics Autoimmune Disease Strategy 2024
investor_presentationinvestor_presentation
25 Pages
Cullinan Therapeutics, Inc.